© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Dapagliflozin Monohydrate stands out in the world of chemical raw materials, primarily as a sodium-glucose co-transporter 2 (SGLT2) inhibitor. Developed for managing type 2 diabetes, its active pharmaceutical ingredient works by helping the body remove excess glucose through urine, setting it apart from other oral antidiabetics. The molecule's importance comes from its selective inhibition, which means it zeroes in on kidney-based processes without meddling with insulin secretion or sensitivity.
The compound carries the molecular formula C21H25ClO6 with an added water molecule, giving it the full specification C21H25ClO6·H2O. Accurate chemical characterization shows a molecular weight near 408.88 g/mol for the parent compound, while the monohydrate aspect adds a slight difference. Its structure contains a chlorophenyl group and a C-glucoside link, features aiding both efficacy and solubility in pharmaceutical form. The three-dimensional configuration, set by several chiral centers, should not be underestimated as this spatial arrangement impacts both physical properties and biological activity.
At room temperature, Dapagliflozin Monohydrate typically appears as a white to off-white crystalline solid. Depending on production methods, some batches may form as tiny flakes, powder, or even fine crystals, though a powdery texture tends to dominate because it promotes better handling and mixing during pharmaceutical manufacturing. These physical forms directly impact dissolvability and flow in tableting machines, a matter visible in manufacturing plants struggling with sticky granulation or inconsistent blending. Chemists recording density values often find about 1.2 to 1.4 g/cm³, making it denser than many organic solvents but manageable on standard lab scales.
Dapagliflozin Monohydrate displays moderate stability in sealed containers, resisting breakdown under standard storage conditions. Sensitivity to light and moisture, while not extreme, always warrants extra care—leaving open jars on benches leads to gradual water uptake, sometimes clumping, which complicates precise weighing or solution preparation. Dissolution occurs in select polar solvents like dimethyl sulfoxide (DMSO) or methanol, with only partial solubility in water at room temperature, a trait that influences both pharmaceutical formulation and waste handling protocols. Heated well above typical processing temperatures, decomposition begins, releasing gases and sometimes forming harmful byproducts, like hydrochloric acid in trace amounts, so lab teams depend on fume hoods for safety.
While Dapagliflozin Monohydrate rarely comes as a bulk liquid under typical conditions, labs and production sites encounter it most as a solid—powders and crystals paving the way for consistent measurement and smooth tablet compression. Occasionally, suppliers deliver it as compact flakes or small pearls, each form carrying pros and cons for downstream usability. Powders mix quickly but sometimes create dust, urging the use of gloves and masks. Crystals, though beautiful under a microscope, command extra time for grinding or homogenization, slowing batch prep on busy days. No supplier in the pharmaceutical supply chain delivers Dapagliflozin Monohydrate as a ready-to-use solution—so each production environment manages its dissolution processes on-site, keeping a close eye on concentrations for safe, regulated dosing.
The density, usually around 1.35 g/cm³, means a scoop heavier than many expect—impacting both warehouse storage and production line logistics. Bulk handling teams typically store the product in tightly sealed drums, lined to prevent environmental moisture absorption and chemical cross-contamination. Dissolution into pharmaceutical buffers or solvents takes time and careful stirring, as undissolved clumps skew concentration calculations if rushed. Even small differences in powder granularity affect mixing speed and uniformity—a reality any process chemist will confirm after cleaning out stuck powder from agitator blades.
Global shipping relies on clear regulatory labeling, and Dapagliflozin Monohydrate fits under the HS Code 293299, reserved for other heterocyclic compounds. Customs agents and compliance officers look for precise documentation, since unregistered imports can choke delivery schedules or trigger compliance audits. Keeping up with evolving regulations sometimes feels like a never-ending paper chase, but these checks maintain safety from manufacturing to final prescription.
Despite its status as a life-changing pharmaceutical, Dapagliflozin Monohydrate requires careful handling. Inhalation or direct skin contact irritates some workers, prompting strict adherence to safety protocols—a lesson learned quickly in labs where unfamiliarity with hazardous dusts leads to rashes or lingering coughs. Spills on benches or warehouse floors get immediate attention, not just to protect workers, but to prevent accidental contamination of other pharmaceutical stock. Long-term environmental effects remain an area for ongoing research, yet by current industry standards, neutralizing waste streams in the plant prevents any harmful residues from entering wastewater or landfill sites. Safety data sheets underline the importance of gloves, goggles, and dust masks, especially on days when multiple batches run in tight quarters.
Here, Dapagliflozin Monohydrate finds its place as a key raw material for pharmaceutical companies producing diabetes therapies. It represents a bridge between complex organic synthesis and lifesaving patient outcomes. Every delivery, from powder to crystal form, starts as the backbone for finished tablets, contributing to standardized efficacy across global markets. Down the line, even the smallest variance in powder density or purity can lead to big shifts in how well a medication controls blood sugar—driving home the necessity of routine quality control. The process chemists, supply managers, and quality assurance teams behind the product all know the critical nature of this molecule and its transformative impact on modern healthcare.
In pharmacology, molecular specificity isn’t just a buzzword thrown around in white papers. Dapagliflozin Monohydrate’s intricate molecular structure—especially its array of chiral centers—defines how it binds in the human body. Companies investing millions in research and downstream production build that trust on precise molecular fingerprints. Analytical chemists test every batch to confirm that structure holds steady, as even the slightest impurity threatens an entire production run. I recall seeing how a minor deviation in the synthesis pathway led to days of troubleshooting and lost product—a reminder that getting the chemistry right isn’t just about science, but about keeping supply chains running and hospitals stocked.
